Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMEA Biomea Fusion	$1.55 +7.6%	$1.80	$1.29 ▼ $13.07	$58.24M	-0.07	900,535 shs	590,854 shs
IMRX Immuneering	$1.87 +9.4%	$1.40	$1.00 ▼ $3.83	$67.29M	-0.22	2.33 million shs	250,774 shs
OTLK Outlook Therapeutics	$1.77 -3.8%	$1.49	$0.87 ▼ $9.25	$61.77M	0.39	775,217 shs	1.78 million shs
RLYB Rallybio	$0.29 -7.4%	$0.34	$0.22 ▼ $1.73	$11.91M	-1.28	111,328 shs	284,069 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMEA Biomea Fusion	+7.64%	+4.73%	-28.90%	-43.84%	-85.27%
IMRX Immuneering	+11.31%	+21.43%	+50.81%	+26.35%	+34.53%
OTLK Outlook Therapeutics	-4.32%	+10.63%	+14.19%	+20.41%	-74.96%
RLYB Rallybio	-8.80%	-13.09%	-9.72%	-60.23%	-82.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMEA Biomea Fusion	2.9633 of 5 stars	3.5	0.0	3.8	3.3	1.3
IMRX Immuneering	3.8259 of 5 stars	3.3	5.0	3.4	3.3	1.3
OTLK Outlook Therapeutics	1.8625 of 5 stars	3.4	3.0	1.9	0.0	0.6
RLYB Rallybio	3.0155 of 5 stars	3.0	4.0	3.3	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMEA Biomea Fusion	3.09	Buy	$22.60	1,358.06% Upside
IMRX Immuneering	2.50	Moderate Buy	$15.33	719.96% Upside
OTLK Outlook Therapeutics	2.80	Moderate Buy	$10.20	476.27% Upside
RLYB Rallybio	2.00	Hold	$10.00	3,394.06% Upside

Current Analyst Ratings Breakdown

Latest RLYB, OTLK, BMEA, and IMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	OTLK Outlook Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/15/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/7/2025	IMRX Immuneering	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $21.00
5/6/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00
5/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/6/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/15/2025	RLYB Rallybio	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/13/2025	RLYB Rallybio	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/10/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/9/2025	RLYB Rallybio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
4/8/2025	RLYB Rallybio	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$4.74 per share	N/A
IMRX Immuneering	$320K	210.29	N/A	N/A	$3.09 per share	0.61
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	($1.57) per share	N/A
RLYB Rallybio	$848K	14.04	N/A	N/A	$2.81 per share	0.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMEA Biomea Fusion	-$117.25M	-$3.55	N/A	N/A	N/A	N/A	-118.90%	-93.66%	7/30/2025 (Estimated)
IMRX Immuneering	-$53.47M	-$1.96	N/A	N/A	N/A	N/A	-79.19%	-69.08%	8/5/2025 (Estimated)
OTLK Outlook Therapeutics	-$75.37M	-$0.91	N/A	N/A	N/A	N/A	N/A	-225.12%	8/13/2025 (Estimated)
RLYB Rallybio	-$74.56M	-$1.09	N/A	N/A	N/A	N/A	-77.39%	-69.33%	8/14/2025 (Estimated)

Latest RLYB, OTLK, BMEA, and IMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q2 2025	OTLK Outlook Therapeutics	-$0.55	-$0.40	+$0.15	-$1.50	$0.70 million	N/A
5/8/2025	Q1 2025	RLYB Rallybio	-$0.21	-$0.21	N/A	-$0.21	N/A	$0.21 million
5/5/2025	Q1 2025	BMEA Biomea Fusion	-$0.84	-$0.80	+$0.04	-$0.80	N/A	N/A
5/5/2025	Q1 2025	IMRX Immuneering	-$0.41	-$0.42	-$0.01	-$0.42	N/A	N/A
3/31/2025	Q4 2024	BMEA Biomea Fusion	-$1.00	-$0.81	+$0.19	-$0.81	N/A	N/A
3/20/2025	Q4 2024	IMRX Immuneering	-$0.42	-$0.58	-$0.16	-$0.58	N/A	N/A
3/13/2025	Q4 2024	RLYB Rallybio	-$0.27	-$0.25	+$0.02	-$0.25	$0.15 million	$0.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMEA Biomea Fusion	N/A	3.39	3.39
IMRX Immuneering	N/A	7.99	7.99
OTLK Outlook Therapeutics	N/A	0.32	0.64
RLYB Rallybio	N/A	9.55	9.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMEA Biomea Fusion	96.72%
IMRX Immuneering	67.65%
OTLK Outlook Therapeutics	11.20%
RLYB Rallybio	90.34%

Insider Ownership

Company	Insider Ownership
BMEA Biomea Fusion	27.57%
IMRX Immuneering	25.00%
OTLK Outlook Therapeutics	4.80%
RLYB Rallybio	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMEA Biomea Fusion	50	37.57 million	26.25 million	Optionable
IMRX Immuneering	60	35.99 million	23.29 million	Not Optionable
OTLK Outlook Therapeutics	20	33.57 million	30.48 million	Optionable
RLYB Rallybio	40	41.61 million	38.42 million	Not Optionable

RLYB, OTLK, BMEA, and IMRX Headlines

Recent News About These Companies

Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook

May 24, 2025 | investing.com

Rallybio shareholders elect directors, ratify auditor

May 18, 2025 | uk.investing.com

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 9, 2025 | finance.yahoo.com

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

April 29, 2025 | finance.yahoo.com

Jones Trading Downgrades Rallybio (RLYB)

April 15, 2025 | msn.com

Rallybio downgraded to Hold from Buy at JonesResearch

April 14, 2025 | markets.businessinsider.com

Rallybio downgraded to In Line from Outperform at Evercore ISI

April 12, 2025 | markets.businessinsider.com

Rallybio (RLYB) was downgraded to a Hold Rating at H.C. Wainwright

April 10, 2025 | markets.businessinsider.com

Rallybio Stock Short Interest Report | NASDAQ:RLYB | Benzinga

April 9, 2025 | benzinga.com

Rallybio discontinues RLYB212 program

April 9, 2025 | markets.businessinsider.com

Rallybio sinks as it drops RLYB212 for prevention of FNAIT

April 9, 2025 | thepharmaletter.com

HC Wainwright & Co. Downgrades Rallybio (RLYB)

April 9, 2025 | msn.com

RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks

April 9, 2025 | zacks.com

Citizens JMP downgrades Rallybio on RLYB212 discontinuation

April 9, 2025 | markets.businessinsider.com

JMP Securities downgrades Rallybio (RLYB) to a Hold

April 9, 2025 | theglobeandmail.com

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

April 8, 2025 | benzinga.com

Rallybio Discontinues Development of Treatment for Prevention of Rare Immune Disorder

April 8, 2025 | marketwatch.com

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

April 8, 2025 | finance.yahoo.com

Rallybio reports Q4 EPS (25c), consensus (30c)

March 13, 2025 | markets.businessinsider.com

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

March 13, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB, OTLK, BMEA, and IMRX Company Descriptions

Biomea Fusion NASDAQ:BMEA

$1.55 +0.11 (+7.64%)

Closing price 06/2/2025 04:00 PM Eastern

Extended Trading

$1.58 +0.03 (+2.26%)

As of 04:08 AM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Immuneering NASDAQ:IMRX

$1.87 +0.16 (+9.36%)

Closing price 06/2/2025 04:00 PM Eastern

Extended Trading

$1.84 -0.03 (-1.34%)

As of 06:27 AM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Outlook Therapeutics NASDAQ:OTLK

$1.77 -0.07 (-3.80%)

Closing price 06/2/2025 04:00 PM Eastern

Extended Trading

$1.82 +0.04 (+2.54%)

As of 07:00 AM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Rallybio NASDAQ:RLYB

$0.29 -0.02 (-7.38%)

Closing price 06/2/2025 04:00 PM Eastern

Extended Trading

$0.28 -0.01 (-2.52%)

As of 06/2/2025 07:21 PM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time